Leveraging EUnetHTA's conceptual framework to compare HTA decision drivers in France, Italy, and Germany from a manufacturer's point of view.

Giuliani, Giovanni; Chassagnol, Frederic; Traub, David; Gyldmark, Marlene; Hebborn, Ansgar; Ducournau, Pierre; Ruof, Jörg

Giuliani, Giovanni; Chassagnol, Frederic; Traub, David; Gyldmark, Marlene; Hebborn, Ansgar; Ducournau, Pierre; Ruof, Jörg.

Afiliação

Giuliani G; Roche S.p.A, Monza, Italy.
Chassagnol F; Roche SAS, Boulogne-Billancourt Cedex, France.
Traub D; Roche Pharma AG, Grenzach-Wyhlen, Germany.
Gyldmark M; F. Hoffmann La Roche, Basel, Switzerland.
Hebborn A; F. Hoffmann La Roche, Basel, Switzerland.
Ducournau P; F. Hoffmann La Roche, Basel, Switzerland.
Ruof J; Medical School of Hanover, Hanover, Germany. joerg.ruof@r-connect.com.

Health Econ Rev ; 8(1): 24, 2018 Sep 21.

Article em En | MEDLINE | ID: mdl-30242522

Palavras-chave

AIFA; Appraisal; EUnetHTA Core model; G-BA; HAS; Health technology assessment; Innovation

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Health_technology_assessment / Prognostic_studies Idioma: En Revista: Health Econ Rev Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Itália País de publicação: Alemanha

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google